One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Corvus Pharmaceuticals, Inc.
CRVS · NGM · Healthcare · Biotechnology
Current price
$9.52
52-week range
$6.39 - $26.95
Market cap
$800.83M
Balance sheet
Healthy
-2,864.73x Concerning
Net cash $214.50M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals develops experimental medicines that aim to help the body's immune system fight diseases like cancer and autoimmune conditions. Their main focus is on testing these potential drugs in clinical trials, which are studies to see if they are safe and effective in people. This means they haven't actually sold any approved medicines yet, so their revenue comes from collaborations with other companies and funding from investors, rather than selling products.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2025 Q1
$-8.30M
FY2025 Q2
$-5.89M
FY2025 Q3
$-9.57M
FY2025 Q4
$-9.22M
FY2026 Q1
$-10.46M
FY2026 Q2
$-15.98M
Revenue
—
Net income
$-17.96M
Diluted EPS
-0.19
Operating cash flow
$-15.40M
Free cash flow
$-15.98M
Fetching…
Sources
Revenue
—
Net income
$-13.69M
Diluted EPS
-0.15
Operating cash flow
$-10.37M
Free cash flow
$-10.46M
Fetching…
Sources
Revenue
—
Net income
$-12.32M
Diluted EPS
-0.18
Operating cash flow
$-9.19M
Free cash flow
$-9.22M
Fetching…
Sources
Revenue
—
Net income
$-10.16M
Diluted EPS
-0.12
Operating cash flow
$-9.57M
Free cash flow
$-9.57M
Fetching…
Sources
Revenue
—
Net income
$-8.00M
Diluted EPS
-0.10
Operating cash flow
$-5.78M
Free cash flow
$-5.89M
Fetching…
Sources
Revenue
—
Net income
$15.19M
Diluted EPS
-0.13
Operating cash flow
$-8.26M
Free cash flow
$-8.30M
Fetching…
Sources
Revenue
—
Net income
$-12.11M
Diluted EPS
-0.23
Operating cash flow
$-8.46M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-40.22M
Diluted EPS
-0.60
Operating cash flow
$-6.32M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $9.52
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $214.5M - more cash than debt. Interest coverage -2864.7x.
Net debt
$-214.50M
Interest coverage
-2,864.73x
Corvus Pharmaceuticals, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
CRVS
BASELINE
Corvus Pharmaceuticals, Inc.
Total debt $728.00K Interest coverage -2,864.73x This is the baseline the peer rows are being compared against.
Total debt $579.86M Interest coverage 0.45x This peer still has a real interest-payment cushion, while CRVS does not.
Total debt $754.39M Interest coverage -10.04x Neither company has much profit cushion over interest right now.
Total debt $30.66M Interest coverage -11.20x Neither company has much profit cushion over interest right now.
Total debt $4.09M Interest coverage -11.69x Neither company has much profit cushion over interest right now.
Total debt $40.11M Interest coverage 78,282.00x This peer still has a real interest-payment cushion, while CRVS does not.
What you should know
The case for and against CRVS
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -35.4% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-8.92x
P/B
3.55x
P/S
—
EV/EBITDA
-10.31x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-35.4%
ROA
-21.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
16.16x
Quick ratio
15.88x
Total debt
$728.00K
Total cash
$215.23M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.62
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-44.53M
Free CF TTM
$-32.97M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—